Exclusion criteria
dyspnea, gastrointestinal bleeding, airway obstruction, erythema, cardiogenic, agitation, hypersensitivity, coma, asthma, skin erythematosus, status post-upper gastrointestinal, ileus
MYOCARDIAL INFARCTION, CARDIOGENIC SHOCK, HEMODYNAMIC INSTABILITY, ERYTHEMA, COMA, ASTHMA, HYPERSENSITIVITY, ILEUS

Patients, on admission, with skin breakdown or non-blanchable erythema in one of the following areas: nasal bridge, nasolabial fold, cheek, or scalp;Patients who refuse to consent to the study protocol;Patient known to be pregnant;Patients with the following contraindications to NIV: lack of spontaneous breathing; gasping; anatomical or functional airway obstruction; gastrointestinal bleeding or ileus; coma; massive agitation; massive retention of secretions despite bronchoscopy and aggressive physiotherapy; hemodynamic instability (e.g., cardiogenic shock, myocardial infarction); status post-upper gastrointestinal surgery;Patients entering the hospital with asthma or cardiogenic pulmonary edema;Patients with tracheostomy;Patients receiving NIV only for palliation of symptoms (e.g., dyspnea relief). These patients belong to category 3 as defined by the Society of Critical Care Medicine (SCCM) Task Force assessing the palliative use of noninvasive positive pressure ventilation [Use of high-flow nasal cannula integrated with NIV to prevent reintubation;Pre-existing skin erythematosus disorders;Known hypersensitivity to skin protective devices (i.e., polyurethane films, colloids, foams);More than 2 h of NIV application before randomization;Patients already included in the study protocol at an earlier stage of their hospital stay; andRefuse to wear NIV interface due to comfort.